-
公开(公告)号：US08088908B2
公开(公告)日：2012-01-03
申请号：US11432304
申请日：2006-05-10
申请人： Mark A. Sherman , Anna M. Wu , Robert E. Reiter
发明人： Mark A. Sherman , Anna M. Wu , Robert E. Reiter
IPC分类号： C07H21/04
CPC分类号： C07K16/3069 , A61K2039/505 , C07K2317/24 , C07K2317/565
摘要： Prostate stem cell antigen (PSCA) is expressed in the majority of prostate cancer patients, making it an ideal target for cancer immunotherapy. Murine monoclonal antibody 1G8 binds to PSCA with nanomolar affinity, but its efficacy as a therapeutic agent is limited by the generation of a HAMA response. The present invention discloses humanized 1G8 antibodies in which the majority of the mouse-derived epitopes have been removed. These humanized antibodies bind PSCA with high affinity and specificity, and have been shown to reduce human bladder tumor take in a nude mouse model. These characteristics make the humanized antibodies of the present invention attractive agents for the treatment and detection of tumors expressing PSCA.
摘要翻译： 前列腺干细胞抗原（PSCA）在大多数前列腺癌患者中表达，使其成为癌症免疫治疗的理想靶标。 鼠单克隆抗体1G8以纳摩尔亲和力结合PSCA，但其作为治疗剂的功效受到HAMA反应的产生的限制。 本发明公开了大部分小鼠来源的表位已被除去的人源化1G8抗体。 这些人源化抗体以高亲和力和特异性结合PSCA，并已显示可以减少人膀胱肿瘤的裸鼠模型。 这些特征使得本发明的人源化抗体用于治疗和检测表达PSCA的肿瘤的吸引剂。
-
公开(公告)号：US08404817B2
公开(公告)日：2013-03-26
申请号：US13308783
申请日：2011-12-01
申请人： Mark A. Sherman , Anna M. Wu , Robert E. Reiter
发明人： Mark A. Sherman , Anna M. Wu , Robert E. Reiter
IPC分类号： C12P21/08
CPC分类号： C07K16/3069 , A61K2039/505 , C07K2317/24 , C07K2317/565
摘要： Prostate stem cell antigen (PSCA) is expressed in the majority of prostate cancer patients, making it an ideal target for cancer immunotherapy. Murine monoclonal antibody 1G8 binds to PSCA with nanomolar affinity, but its efficacy as a therapeutic agent is limited by the generation of a HAMA response. The present invention discloses humanized 1G8 antibodies in which the majority of the mouse-derived epitopes have been removed. These humanized antibodies bind PSCA with high affinity and specificity, and have been shown to reduce human bladder tumor take in a nude mouse model. These characteristics make the humanized antibodies of the present invention attractive agents for the treatment and detection of tumors expressing PSCA.
摘要翻译： 前列腺干细胞抗原（PSCA）在大多数前列腺癌患者中表达，使其成为癌症免疫治疗的理想靶标。 鼠单克隆抗体1G8以纳摩尔亲和力结合PSCA，但其作为治疗剂的功效受到HAMA反应的产生的限制。 本发明公开了大部分小鼠来源的表位已被除去的人源化1G8抗体。 这些人源化抗体以高亲和力和特异性结合PSCA，并已显示可以减少人膀胱肿瘤的裸鼠模型。 这些特征使得本发明的人源化抗体用于治疗和检测表达PSCA的肿瘤的吸引剂。
-
公开(公告)号：US20120077962A1
公开(公告)日：2012-03-29
申请号：US13308783
申请日：2011-12-01
申请人： Mark A. SHERMAN , Anna M. Wu , Robert E. Reiter
发明人： Mark A. SHERMAN , Anna M. Wu , Robert E. Reiter
CPC分类号： C07K16/3069 , A61K2039/505 , C07K2317/24 , C07K2317/565
摘要： Prostate stem cell antigen (PSCA) is expressed in the majority of prostate cancer patients, making it an ideal target for cancer immunotherapy. Murine monoclonal antibody 1G8 binds to PSCA with nanomolar affinity, but its efficacy as a therapeutic agent is limited by the generation of a HAMA response. The present invention discloses humanized 1G8 antibodies in which the majority of the mouse-derived epitopes have been removed. These humanized antibodies bind PSCA with high affinity and specificity, and have been shown to reduce human bladder tumor take in a nude mouse model. These characteristics make the humanized antibodies of the present invention attractive agents for the treatment and detection of tumors expressing PSCA.
摘要翻译： 前列腺干细胞抗原（PSCA）在大多数前列腺癌患者中表达，使其成为癌症免疫治疗的理想靶标。 鼠单克隆抗体1G8以纳摩尔亲和力结合PSCA，但其作为治疗剂的功效受到HAMA反应的产生的限制。 本发明公开了大部分小鼠来源的表位已被除去的人源化1G8抗体。 这些人源化抗体以高亲和力和特异性结合PSCA，并已显示可以减少人膀胱肿瘤的裸鼠模型。 这些特征使得本发明的人源化抗体用于治疗和检测表达PSCA的肿瘤的吸引剂。
-
4.发明授权Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting 有权用于癌症靶向的工程化抗前列腺干细胞抗原（PSCA）抗体公开(公告)号：US08940871B2
公开(公告)日：2015-01-27
申请号：US12293860
申请日：2007-03-20
申请人： Anna M. Wu , Robert E. Reiter
发明人： Anna M. Wu , Robert E. Reiter
CPC分类号： G01N33/57434 , A61K51/1072 , A61K51/1087 , A61K2039/505 , C07K16/3069 , C07K16/464 , C07K2317/526 , C07K2317/622 , C07K2317/64 , C07K2319/30
摘要： The invention provides novel humanized antibody fragments that specifically bind prostate cell-surface antigen (PSCA), a protein which is overexpressed in variety of cancers, including prostate, bladder, and pancreatic cancer. Methods are provided for the use of the compositions of the invention for the treatment of cancer, diagnosis of cancer, to provide a prognosis of cancer progression, and for cancer imaging.
摘要翻译： 本发明提供了特异性结合前列腺细胞表面抗原（PSCA）的新型人源化抗体片段，其是在多种癌症中包括前列腺，膀胱和胰腺癌过表达的蛋白质。 提供了用于本发明组合物用于治疗癌症，诊断癌症，提供癌症进展预后以及癌症成像的方法。
-
5.发明授权High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection 有权用于癌症靶向和检测的高亲和力抗前列腺干细胞抗原（PSCA）抗体公开(公告)号：US08940298B2
公开(公告)日：2015-01-27
申请号：US12676348
申请日：2008-09-04
申请人： Anna M. Wu , Robert E. Reiter , Eric J. Lepin , James D. Marks , Yu Zhou
发明人： Anna M. Wu , Robert E. Reiter , Eric J. Lepin , James D. Marks , Yu Zhou
IPC分类号： A61K39/395 , C07K16/30
CPC分类号： C07K16/3069 , A61K39/39558 , A61K51/1096 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/626 , G01N33/574 , G01N33/57434 , G01N33/57492
摘要： The present invention provides novel high affinity antibodies and fragments thereof that bind to the cancer antigen PSCA. The antibodies of the present invention may be used for cancer diagnosis, prognosis, treatment, visualization, and the like. The present invention also provides methods for the detection, visualization, and treatment of various cancers expressing PSCA.
摘要翻译： 本发明提供结合癌抗原PSCA的新型高亲和力抗体及其片段。 本发明的抗体可用于癌症诊断，预后，治疗，可视化等。 本发明还提供了用于检测，可视化和治疗表达PSCA的各种癌症的方法。
-
公开(公告)号：US20100233170A1
公开(公告)日：2010-09-16
申请号：US12590601
申请日：2009-11-09
申请人： Robert E. Reiter , Eric Lepin , Anna M. Wu
发明人： Robert E. Reiter , Eric Lepin , Anna M. Wu
IPC分类号： A61K39/395 , G01N33/574 , C12N5/10 , C12N15/63 , C07K16/18 , C07H21/04 , A61P35/00 , A61P35/04
CPC分类号： A61K39/3955 , A61K2039/505 , C07K16/2896 , C07K2317/21 , C07K2317/622 , G01N33/574 , G01N33/57434 , G01N33/57484 , G01N2333/70525
摘要： The present application provides fully human antibodies against N-Cadherin for therapeutic and diagnostic methods in cancer.
摘要翻译： 本申请提供了针对N-钙粘蛋白的完全人抗体用于癌症中的治疗和诊断方法。
-
7.发明申请Engineered Anti-Prostate Stem Cell Antigen (PSCA) Antibodies for Cancer Targeting 有权用于癌症靶向的工程化抗前列腺干细胞抗原（PSCA）抗体公开(公告)号：US20090311181A1
公开(公告)日：2009-12-17
申请号：US12293860
申请日：2007-03-20
申请人： Anna M. Wu , Robert E. Reiter
发明人： Anna M. Wu , Robert E. Reiter
IPC分类号： A61K49/00 , C07K16/30 , A61K49/04 , G01N33/574 , A61K39/395
CPC分类号： G01N33/57434 , A61K51/1072 , A61K51/1087 , A61K2039/505 , C07K16/3069 , C07K16/464 , C07K2317/526 , C07K2317/622 , C07K2317/64 , C07K2319/30
摘要： The invention provides novel humanized antibody fragments that specifically bind prostate cell-surface antigen (PSCA), a protein which is overexpressed in variety of cancers, including prostate, bladder, and pancreatic cancer. Methods are provided for the use of the compositions of the invention for the treatment of cancer, diagnosis of cancer, to provide a prognosis of cancer progression, and for cancer imaging.
摘要翻译： 本发明提供了特异性结合前列腺细胞表面抗原（PSCA）的新型人源化抗体片段，其是在多种癌症中包括前列腺，膀胱和胰腺癌过表达的蛋白质。 提供了用于本发明组合物用于治疗癌症，诊断癌症，提供癌症进展预后以及癌症成像的方法。
-
公开(公告)号：US08703920B2
公开(公告)日：2014-04-22
申请号：US12590601
申请日：2009-11-09
申请人： Robert E. Reiter , Eric Lepin , Anna M. Wu
发明人： Robert E. Reiter , Eric Lepin , Anna M. Wu
IPC分类号： C07K14/00 , C07K16/00 , C07K17/00 , A61K35/14 , A61K38/16 , A61K39/395 , A61K39/00 , C12P21/08
CPC分类号： A61K39/3955 , A61K2039/505 , C07K16/2896 , C07K2317/21 , C07K2317/622 , G01N33/574 , G01N33/57434 , G01N33/57484 , G01N2333/70525
摘要： The present application provides fully human antibodies against N-Cadherin for therapeutic and diagnostic methods in cancer.
摘要翻译： 本申请提供了针对N-钙粘蛋白的完全人抗体用于癌症中的治疗和诊断方法。
-
9.发明申请HIGH AFFINITY ANTI-PROSTATE STEM CELL ANTIGEN (PSCA) ANTIBODIES FOR CANCER TARGETING AND DETECTION 有权高亲和力抗前列腺癌细胞抗原（PSCA）用于癌症靶向和检测的抗体公开(公告)号：US20100297004A1
公开(公告)日：2010-11-25
申请号：US12676348
申请日：2008-09-04
申请人： Anna M. Wu , Robert E. Reiter , Eric J. Lepin , James D. Marks , Yu Zhou
发明人： Anna M. Wu , Robert E. Reiter , Eric J. Lepin , James D. Marks , Yu Zhou
IPC分类号： A61K51/10 , C07K16/00 , C12N9/96 , C12N15/13 , C12N5/09 , A61K39/395 , A61K49/00 , A61B5/055 , A61P35/00
CPC分类号： C07K16/3069 , A61K39/39558 , A61K51/1096 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/626 , G01N33/574 , G01N33/57434 , G01N33/57492
摘要： The present invention provides novel high affinity antibodies and fragments thereof that bind to the cancer antigen PSCA. The antibodies of the present invention may be used for cancer diagnosis, prognosis, treatment, visualization, and the like. The present invention also provides methods for the detection, visualization, and treatment of various cancers expressing PSCA.
摘要翻译： 本发明提供结合癌抗原PSCA的新型高亲和力抗体及其片段。 本发明的抗体可用于癌症诊断，预后，治疗，可视化等。 本发明还提供了用于检测，可视化和治疗表达PSCA的各种癌症的方法。
-
公开(公告)号：US07776330B2
公开(公告)日：2010-08-17
申请号：US11861093
申请日：2007-09-25
IPC分类号： A61K39/395 , C12P21/04 , C12P21/08 , C07K16/00
CPC分类号： C07K16/3007 , A61K2039/505 , C07K16/32 , C07K16/465 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/626 , C07K2317/92 , C12N15/1089 , G01N33/574
摘要： Embodiments of the present invention utilize a more efficient CDR grafting technique to generate humanized versions of the T84.66 antibody. The technique used to generate these antibodies utilizes crystallographic structural data to select an immunoglobulin framework having maximum structural overlap with a non-human donor molecule. This technique was used to develop humanized T84.66 antibodies exhibiting in vitro binding affinity and specificity for carcinoembryonic antigen (CEA) nearly identical to that of T84.66 and the ability to specifically target tumors expressing CEA in vivo.
摘要翻译： 本发明的实施方案利用更有效的CDR移植技术来产生人源化版本的T84.66抗体。 用于产生这些抗体的技术利用晶体结构数据来选择与非人供体分子具有最大结构重叠的免疫球蛋白框架。 该技术用于开发显示与T84.66几乎完全相同的癌胚抗原（CEA）的体外结合亲和性和特异性的人源化T84.66抗体，并且具体靶向体内表达CEA的肿瘤的能力。
-
-
-
-
-
-
-
-
-
搜索结果
32 条记录 (耗时 0.031 秒)
